Anticoagulants among most common causes of adverse events | Dabigatran with certain statins tied to increased bleeding risk in AFib | Post-birth microcephaly found in infants with Zika syndrome
ADVERTISEMENT
November 23, 2016
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP ⋅   FORWARD
Top Story
Anticoagulants among most common causes of adverse events
A CDC study in the Journal of the American Medical Association found one in 250 Americans visited emergency departments due to adverse drug events annually in 2013 and 2014, an increase from 2005 and 2006. Anticoagulants, antibiotics and diabetes drugs accounted for nearly half of the cases, according to data for 42,585 emergency room visits. For adverse events related to anticoagulants, hemorrhage was documented in about 80% of emergency department visits.
Medscape (free registration) (11/22),  CNN (11/22) 
LinkedIn Twitter Facebook Google+ Email
Immucor is Your Partner in Continuing Education
Immucor invests in partnerships with you to improve ongoing education initiatives via our online education website, LEARN. LEARN offers you the flexibility to take courses at your convenience and provides complimentary CE credits for you and your staff. Visit the LEARN website or contact your local Blood Bank Business Manager for more information.
ADVERTISEMENT
Science & Health
Dabigatran with certain statins tied to increased bleeding risk in AFib
A study in the Canadian Medical Association Journal found patients with atrial fibrillation who used dabigatran, or Pradaxa, along with simvastatin or lovastatin had an increased risk of major bleeding compared with those who used the drug with other cholesterol-lowering statins. The findings, based on nearly 46,000 Ontario residents aged 66 and older, showed patients who were older than 75 and had kidney problems had the highest bleeding risk associated with dabigatran.
Reuters (11/21) 
LinkedIn Twitter Facebook Google+ Email
Post-birth microcephaly found in infants with Zika syndrome
Eleven of 13 Brazilian infants with congenital Zika syndrome and normal head circumference at birth developed microcephaly in the following months. A report in the CDC's Morbidity and Mortality Weekly Report said the infants had a range of symptoms of congenital Zika syndrome, including muscle and joint problems and difficulty moving and swallowing.
The New York Times (free-article access for SmartBrief readers) (11/22),  Reuters (11/22) 
LinkedIn Twitter Facebook Google+ Email
Embrace Disruptive Innovation
Traditional business is constantly being impacted by overwhelming and sudden shifts in the marketplace. This new normal is "disruptive innovation". Read this white paper to learn what disruptive innovation is and how your company can use cloud ERP to stay in the game.
Download the white paper >
ADVERTISEMENT
Emerging Trends
Malaria prevention drugs to older youths may curb transmission, study finds
A study by the London School of Hygiene & Tropical Medicine and Senegal's Cheikh Anta Diop University found that providing seasonal malaria chemoprevention to youths older than 5 in Senegal during a high malaria season decreased cases by more than 50% in children up to age 10 and 26% in youths older than 10. The findings also showed that accommodating older children in SMC interventions didn't substantially increase treatment delivery time.
Reuters (11/22) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
Novartis acquires sickle cell drug candidate with Selexys purchase
Novartis is making a $665 million purchase of Selexys Pharmaceuticals following Phase II trial results for SelG1, an anti-P-selectin monoclonal antibody to treat sickle cell disease. Other drugmakers are testing sickle cell medications as well, including GlycoMimetics and Pfizer.
PMLive.com (U.K.) (11/21) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
Officials declare part of Miami Beach Zika-free
Public health officials say there have been no locally transmitted cases of Zika virus in 45 days in a three-mile section of Miami Beach, and the virus is no longer circulating there, although Little River and the southernmost area of Miami Beach remain problem areas. However, people who live in or visit any part of Miami-Dade County, including Miami Beach, should take protective steps, CDC Director Dr. Tom Frieden says.
USA Today (11/22),  The Wall Street Journal (tiered subscription model) (11/22) 
LinkedIn Twitter Facebook Google+ Email
FDA puts Arrowhead's trial for HBV drug on clinical hold
Arrowhead Pharmaceuticals' Phase IIb trial for ARC-520, a drug candidate intended to treat hepatitis B infection, has been put on clinical hold by the FDA after several primates died in a toxicology study in which the drug was administered using EX1, a synthetic delivery vehicle. The firm said the cause of the primates' deaths is still under investigation.
InPharm.com (11/18) 
LinkedIn Twitter Facebook Google+ Email
Association News
Submit educational program proposals for the 2017 AABB Annual Meeting
The Annual Meeting Education Committee is soliciting proposals for educational programs to be presented at the 2017 AABB Annual Meeting, to be held Oct. 7-10, 2017, in San Diego, Calif. We now have new educational tracks and topics for you to choose from, and we have enhanced our proposal submission site. All submissions must be received by Jan. 6, 2017. Submit your proposal today!
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
Editor's Note
SmartBrief will not publish Thursday, Friday
In observance of Thanksgiving in the US, SmartBrief will not publish Thursday and Friday. Publication will resume Monday.
LinkedIn Twitter Facebook Google+ Email
  
  
Birds sing after a storm. Why shouldn't people feel as free to delight in whatever sunlight remains to them?
Rose Kennedy,
philanthropist
LinkedIn Twitter Facebook Google+ Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information